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Background: The purpose of the study was to determine the incidence of gene expression of Oct-4 and DAZL,
which are typical markers for stem cells, in human granulosa cells during ovarian stimulation in women with
normal FSH levels undergoing IVF or ICSI and to discover any clinical significance of such expression in ART.
Methods: Twenty one women underwent ovulation induction for IVF or ICSI and ET with standard GnRH
analogue-recombinant FSH protocol. Infertility causes were male and tubal factor. Cumulus–mature oocyte
complexes were denuded separately and granulosa cells were analyzed for each patient separately using
quantitative reverse-transcription–polymerase chain reaction analysis for Oct-4 and DAZL gene expression with
G6PD gene as internal standard.
Results: G6PD and Oct-4 mRNA was detected in the granulosa cells in 47.6% (10/21). The median of Oct-4 mRNA/
G6PD mRNA was 1.75 with intra-quarteral range from 0.10 to 98.21. The OCT-4 mRNA expression was statistically
significantly correlated with the number of oocytes retrieved; when the Oct-4 mRNA expression was higher, then
more than six oocytes were retrieved (p=0.037, Wilcoxon rank-sum). No detection of DAZL mRNA was found in
granulosa cells. There was no additional statistically significant correlation between the levels of Oct-4 expression
and FSH basal levels or estradiol peak levels or dosage of FSH for ovulation induction. No association was found
between the presence or absence of Oct-4 mRNA expression in granulosa cells and ovarian response to
gonadotropin stimulation. Also, no influence on pregnancy was observed between the presence or absence of
Oct-4 mRNA expression in granulosa cells or to its expression levels accordingly.
Conclusions: Expression of OCT-4 mRNA, which is a typical stem cell marker and absence of expression of DAZL
mRNA, which is a typical germ cell marker, suggest that a subpopulation of luteinized granulosa cells in healthy
ovarian follicles (47.6%) consists of stem cells, which are not originated from primordial germ cells. Absence of
Oct-4 gene expression in more than half of the cases means probably the end of the productive journey of these
cells, towards the oocyte.
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The adult human ovary is composed of various cell
types. Within the follicle, paracrine communications
between oocyte, granulosa cells and thecal cells are crit-
ical for normal follicular development and further ferti-
lizability [1-6]. The paracrine factors, maintained by the
gonadotrophins, allow for a dialogue between oocyte
and granulosa cells through gap junctions, promote
granulosa cells differentiation, affect the pattern of gene* Correspondence: mnvarras@otenet.gr
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reproduction in any medium, provided the orexpression and contribute to oocyte maturation [5,7-13].
Kossowska-Tomaszczuk et al. (2009) demonstrated the
presence of multipotent granulosa cells, which survive in
the presence of leukemia-inhibiting factor (LIF) and sug-
gested that the follicular granulosa cells consist of sub-
populations of differentiated and less differentiated cells
[14]. Also, some studies have showed regeneration of
oocytes from putative germ cells in bone marrow and
peripheral blood or even from somatic stem cells
[15,16]. It is not clear yet if the follicular granulosa cells
could serve as a new source for germ cells.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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features of oocytes that can predict whether IVF
fertilization will be successful, or whether there is a need
for ICSI [17]. Moreover, in the field of assisted
reproduction, the selection of embryos with high implan-
tation potential remains one of the major goals in order to
transfer one embryo and avoid therefore the adverse out-
comes related to multiple pregnancies [5]. However, the
study of human oocytes is limited by their complex avai-
lability and their low number, while granulosa are easily
available since they are always discarded before ICSI pro-
cedures [5]. Recently the use of ICSI in cases unrelated to
male factor infertility has increased greatly at ART facil-
ities [17-19]. Such general use of ICSI, however, raises
concerns because of its greater costs, such as the increase
in the risk of transmitting chromosomal anomalies or
imprinting disorders [20-22], although it is not clear
whether these risks are due to the procedure or to the fac-
tors causing male infertility [17,23]. In view of the concept
of the beneficial effect of granulosa cells on oocyte matu-
ration, the need for greater understanding of the mechan-
isms involved in late oogenesis and the need for
independent prognostic markers of better outcomes using
conventional IVF for couples with non-male factor infer-
tility, we focused on Oct-4 and DAZL as target genes in
luteinized granulosa cells of the human ovaries.
Octamer-binding transcription factor-4 (Oct-4, also
known as POU5F1) is a member of Pit-Oct-Unc (POU)
transcription factor family [24,25]. Oct-4 is expressed in
whole embryos at different stages of development, em-
bryonic stem (ES) cells, germ cells, embryonal and
germ-cell tumors, such as embryonal carcinoma (EC),
testicular carcinoma in situ, dysgerminoma, seminoma,
and embryonal carcinoma component of nonseminoma-
tous cell tumor [26-35]. Embryoid bodies from mouse
stem cells are found to express Oct-4 gene [36]. Also,
during early mouse preimplantation development, Oct-4
is expressed in all blastomeres and at blastocyst stage it
is confined to inner cell mass and is down-regulated in
trophectoderm. After implantation, Oct-4 expression is
restricted to the epiblast, is down-regulated during gas-
trulation, and is later confined to primordial germ cells
[29,33,37,38]. During fetal, newborn, and adult sperm-
atogenesis, Oct-4 expression is limited to most undiffer-
entiated spermatogonia [38]. In fetal ovaries, Oct-4
expression ceases soon after the germ cells have
entered meiosis, it reappears before the beginning of
oocyte growth and then is maintained throughout folli-
culogenesis [33]. Oct-4 in co-operation with other fac-
tors (e.g. FOXD3, SOX2, STAT3) regulates tissue- and
cell-specific transcription via the consensus motif
ATGCAAAT [30,39-42]. The Oct-4 gene contains the
proximal enhancer (PE) and the distal enhancer (DE)
that are important for Oct-4 cell type-specificexpression, and the four conserved domains CR1-CR4,
that are important for Oct-4 basal expression [43]. Oct-
4 expression is restricted to pluripotent cells, while the
loss of Oct-4 expression may be associated with loss of
pluripotentiality [41]. Oct-4 is involved in the self-
renewal of undifferentiated embryonic stem cells and is
therefore used as a marker of embryonic stem cells
[25,28,39,40,44].
The protein DAZL (DAZ-like) is RNA binding protein
which is a member of the DAZL (deleted in azoospermia
like) family which also includes BOULE and DAZ. The
genes of the DAZL family encode proteins with a highly
conserved RNA-binding motif (RNA recognition motif,
RRM) and a unique DAZ repeat of 24 amino acids. These
proteins are believed to function in the post-transcriptional
regulation of messenger RNA (mRNA) expression [45-48].
The proteins of the DAZL family are located to nucleus and
cytoplasm of the fetal germ cells [49]. In the male, DAZL is
expressed during spermatogenesis in gonocytes, spermato-
gonia and primary spermatocytes. During meiosis, DAZL is
translocated from the nucleus of the spermatogonia into
the cytoplasm of secondary spermatocytes, spermatids and
spermatozoa [50-53]. During oogenesis, human DAZL is
expressed in the cytoplasm of oogonia and in developing
follicular oocytes in fetal and adult ovaries [54-58].
Targeted deletion of the DAZL gene results in germ cell
loss in both males and females in humans and mice [52].
In DAZL −/− females germ cell loss occurred in fetal ovar-
ies at the time of meiotic entry and adult ovaries did not
contain oocytes [52,59]. In DAZL −/− males the pattern of
germ cell loss is variable and in some studies it has been
reported to occur during fetal life, whilst in others it was
associated with spermatogonial differentiation or entry to
meiosis [46,48,51,60,61]. In human males, decreased DAZL
expression has been reported in testes which produce little
or no sperm [62] and may be associated with primary
amenorrhea or premature ovarian failure in women [54,63].
Not unique to germ cells, DAZL transcripts are also found
in somatic Sertoli cells of the gonad [63-65]. DAZL has also
been reported to be expressed in human and mouse granu-
losa cells [52,54], human theca interna cells [55] and in the
granulosa-luteal cells of human corpus lutea [59,66], but
this remains controversial [67]. In addition, DAZL and
Oct-4 gene expression has been found in human amniotic
fluid cells promising the potential of these cells as a multi-
potent cell course for regenerative somatic cell therapy, and
very recently DAZL expression has been found in mouse
bone marrow mesenchymal cells [49,68].
The purpose of this study was to investigate whether
human luteinized follicular granulosa cells contain cells
expressing the transcription factors Oct-4 or DAZL and
whether there is any relationship between the expressed
genes and the infertile clinical features and outcomes
after IVF or ICSI and embryo transfer (ET).
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Participants
21 women who had undergone to IVF or ICSI and ET
were enrolled in the study in order to determine the ex-
pression of Oct-4 and DAZL mRNA in their ovarian fol-
licular granulosa cells. Among them, 13 cases (62%)
underwent IVF due to tubal disease and 8 cases (38%)
underwent ICSI due to male infertility. The patients
were submitted to the same ovulation protocol. Women
with history of diabetes mellitus and/or polycystic ovar-
ian syndrome (PCOS), as well as women with endomet-
riosis were excluded from the study. The study received
approval from the hospital’s ethics committee, and writ-
ten informed consent was obtained from the participants
of this study. Details for the hormone assays are given in
the recent manuscript by Varras et al. [69].
Interventions
The protocol for controlled ovarian hyperstimulation
and follicle monitoring, have previously been described
[69]. In order to determine Oct-4 and DAZL mRNA ex-
pression, cumulus cells were collected during oocyte re-
trieval. The cells were segregated from cumulus-mature
oocyte complexes (CMOCs) through the process of
stripping using a fire-polished tip glass pipette. The se-
lection of the cumulus-mature oocyte complexes
(CMOCs) before cell isolation was random. RNA was
extracted using the RNeasy Micro Kit (Qiagen, Valencia,
CA, USA). RNA extraction was conducted according to
manufacturer’s protocol. The extracted RNA was a prod-
uct of cumulus cells pooled from several CMOCs and
not only from the oocytes that proceeded to embryo
transfer. Moreover, RNA concentration of each sample
was determined by spectrophotometry and its quality was
evaluated by agarose gel electrophoresis. cDNA preparation
was performed using 20 ng aliquots of total RNA extracted.
RNA was reverse-transcribed using 0.5 mM dNTP mix
(Ambion, Austin, Tx, USA), 5 μM oligo dT Primer
(Ambion, Austin, Tx, USA), 1xRT buffer (Ambion, Austin,
Tx, USA), 80 U ribonuclease inhibitor (Invitrogen Life
Technologies), 1600 U M-MLV reverse transcriptase (Invi-
trogen Life Technologies) and nuclease free water
(Ambion, Austin, Tx, USA) to a total volume of 40 μl. The
reactions were carried out in Mastercycler (Eppendorf)
with the following conditions: 80°C for 3 min, 42°C for 60
min and 92°C for 10 min. The resulting cDNAs were
stored at −20°C.
The expression of Oct-4 and DAZL mRNA in lutei-
nized granulosa cells were assessed by real-time PCR
using sense and antisense primer pairs and hybridization
probes particularly synthesized by TIB-MOLBIOL for
this study. Primers (Sense and Antisence) and fluro-
scent Probes (FL and LC) sequences are seen in Figures 1
and 2. The specific primers and probes were used atconcentrations 20 pmol/μl for each reaction. To deter-
mine the steady amount for Oct-4 and DAZL mRNA
levels in granulosa cells, a quantitative competitive PCR
(QC RT-PCR) was developed using a LightCycler 480
(Roche). Samples were run in duplicate and no template
controls were included in all runs to exclude possible
DNA contaminations. The 20μl RT-PCR reaction mix-
ture contained 4μL Light Cycler 480 Genotyping Master
(Roche), 0.5μL of each primer, 0.2 μl of each probe, 9.6 μl
H2O of LightCycler 480 Genotyping Master (Roche)
and 5μl of cDNA. The expression of Oct-4 and DAZL
genes were normalized with the data for G6PD (Light
Mix Kint G6PD, TIB MOLBIOL). The respective quan-
titative ratio was determined by the density of each tar-
get to the internal standard: Oct-4mRNA/G6PDmRNA
and DAZLmRNA / G6PDmRNA. PCR was performed on
Light Cycler 480 (Roche) with the following parameters:
one cycle at 95°C for 10-sc for pro-incubation, 40 cycles
for amplification (95°C for 10 sc, 56°C for 20 sc, 72°C for
10 sc) and one cycle at 4°C for cooling.
Statistical analyses
All statistical analyses were performed using the STATA
9 statistical software. Differences between qualitative/
categorical variables were evaluated with the Fisher’s
exact test. Non-parametric Wilcoxon rank-sum and
Kruskal-Wallis tests were used to compare differences of
quantitative variables between categories of qualitative
variables. The Spearman rank correlation coefficient
(Spearman’s rho) was used to analyze the relationship
between two different values. Multiple linear regression
analysis and multiple logistic regression analysis were
performed to determine the relationship between the




The average age of the patients was 35.52 ± 4.06 years,
the average BMI was 23.08 ± 4.35, the average basal FSH
levels (IU/l) were 6.66 ±2.52 and the average prolactin
(PRL) levels (ng/ml) were 12.97±7.32. The Table 1 pre-
sents additional demographic and clinical parameters.
Fertilization was successful in all cases in the laboratory
(21/21). A pregnancy test was positive in 29% (n=6) of
cases and a clinical pregnancy was confirmed in 19%
(n=4) of women. No multiple pregnancies were observed,
while a first trimester abortion and an ectopic pregnancy
occurred in 1 case each. Positive pregnancy test was
found in 4 cases in the ICSI group and in 2 cases in the
IVF group. Clinical pregnancy was found in 2 cases in
each group. The median for age in the ICSI group was
37.0 (IQR: 34.5-38.5), while in the IVF group was 36.0
(IQR: 35.0-36.0). The median for PRL in the ICSI group
Figure 1 mRNA sequences for Oct-4 genes. Sense and antisense mRNA sequences for Oct-4; (Tm: Melting temperature).
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(IQR: 8.8-21.9). The median for estradiol levels (pg/ml) the
fifth day of rFSH administration in the ICSI group was
449.5 (IQR: 309.0-638.0), while in the IVF group was 508.0
(IQR: 350.0-933.0). The median number of oocytes
retrieved in the ICSI group was 8.5 (IQR: 6.0-9.5), while in
the IVF group was 7.0 (IQR: 6.0-9.0).
Incidence of Oct-4 gene expression and absence of DAZL
gene expression in granulosa cells
Oct-4 gene expression in luteinized granulosa cells in
women that underwent IVF or ICSI was observed in 48%
of the studied cases (10 out of 21). In the 10 cases, in which
the Oct-4 gene was expressed, the median Oct-4 mRNA/
G6PD mRNA was 1.75 (quartile range 0.10 – 98.21). On
the other hand, no DAZL gene expression was observed in
any of the 21 cases studied.
Expression of Oct-4 gene in granulosa cells according to
clinical parameters
There were no significant differences among the pres-
ence or absence of Oct-4 gene expression and age, BMI,
years and causes of infertility, previous assisted
reproduction attempts, basal serum FSH and LH levels,
serum levels of PRL, serum oestradiol levels on the fifth
day of rFSH administration and on the day of hCG ad-
ministration, the total dose of rFSH, the duration of
treatment, the type of assisted reproduction, the number
of follicles aspirated, the total number of oocytes
retrieved, the number of mature oocytes retrieved, the
mature oocytes ratio (<60%, 60-75% and ≥75%), the
embryo grade, the positive pregnancy test and the exist-
ence of clinical pregnancy (Tables 2 and 3).
In addition, the above parameters were examined in
relation to the levels of Oct-4 mRNA expression in gran-
ulosa cells. There was a trend for negative correlation
between the basal serum levels of FSH and the Oct-4
mRNA expression levels, however it did not reach statis-
tically significantly (Spearman’s rho=−0.614, p=0.059)
(Figure 3). Also, a non-significant trend for positiveFigure 2 mRNA sequences for DAZL genes. Sense and antisense mRNAcorrelation was recorded between the peak levels of es-
tradiol on the day of hCG administration and the levels
of Oct-4 mRNA expression (Spearman’s rho=0.588,
p=0.074) (Figure 4). The Oct-4 mRNA expression was
statistically significantly correlated with the number of
oocytes retrieved; when the Oct-4 mRNA expression
was higher, then more than six oocytes were retrieved
(p=0.037, Wilcoxon rank-sum). No other significant cor-
relation between Oct-4 mRNA expression and total go-
nadotropin dose and number of mature oocytes
aspirated was found.
Multiple regression analysis was performed to examine
possible contributing factors. When embryo grade
(grade 3, grade 3+2, grade 2) was used as the dependent
variable, whereas age (ys), PRL (ng/ml), estradiol levels
the fifth day of rFSH administration (pg/ml) and levels
of Oct-4/G6PD mRNA expression as independent vari-
ables, only estradiol levels on the fifth day of rFSH ad-
ministration and total rFSH dose administrated were
significantly related to the embryo grade (p=0.040 and
p=0.029 respectively) (Table 4). Additionally, when the
clinical pregnancy was used as dependent variable and
the above parameters as independent variables no corre-
lations were found to be statistically significant
(Table 5).
Discussion
The present study showed the expression of Oct-4 in
luteinized granulosa cells of women that underwent IVF
or ICSI. To the best of our knowledge, this is the first re-
port which determined the frequency of Oct-4 in these
cells and investigated the correlations between the pres-
ence or absence and the levels of Oct-4 gene expression
with infertility clinical background and the assisted
reproduction outcomes [14]. Kossowska et al. [14], in
order to get past the fact that the status of infertility of
individual patients might affect the function of granulosa
cells, pooled granulosa cells from all the different
patients who studied and examined the expression of
POU5F1 in the sum of cells. Therefore, the presentsequences for DAZL genes; (Tm: Melting temperature).
Table 1 Patient characteristics
Characteristics Median (IQR)
Infertility duration (years) 4.00 (3.00–6.50)
Serum LH (IU/L) 4.60 (3.36–8.40)
Total gonadotropin dose (IU) 2,875.00 (2,037.50–3,587.50)
Duration of stimulation (days) 10.00 (9.00-11.00)
Serum estradiol on the 5th day
of rFSH administration (pg/ml)
500.00 (309.00 – 758.00)
Serum estradiol on the day of
hCG administration (pg/ml)
1,910.00 (1,570.00–2,467.00)
Number of follicles aspirated 8.00 (6.00-10.00)
Grade 2 embryos 0.00 (0.00-2.00)
Grade 3 embryos 4.00 (4.00-6.00)
High quality embryo ratio (%) 100.00 (66.67 – 100.00)
Patients’ demographics and clinical parameters.
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expression of the Oct-4 in luteinized granulosa cells,
which is detected in almost half of the cases. The ex-
pression of Oct-4, in granulosa cells reported herein, is
in agreement with the previous findings from Kossowska
et al. [14], and reinforces the implication that the granu-
losa cells of healthy follicles are not uniform but consist
of two distinct subpopulations of differentiated and less
differentiated cells, with the less differentiated cells being
capable of mitosis. The expression of Oct-4 supports theTable 2 Oct-4 expression – baseline characteristics and
outcomes
Οct-4 expression p-
value*No n (%) Yes n (%)
Infertility Cause 0.864
Male 4 (36.4) 4 (40.0)
Fallopian tube 7 (63.6) 6 (60.0)
Previous IVF/ICSI cycles 0.525
No 9 (81.8) 7 (70.0)
Yes 2 (18.2) 3 (30.0)
Embryos grade 0.296
3 9 (81.8) 5 (50.0)
3 + 2 1 (9.1) 3 (30.0)
2 1 (9.1) 2 (20.0)
Positive pregnancy test 0.269
No 9 (81.8) 6 (60.0)
Yes 2 (18.2) 4 (40.0)
Clinical pregnancy 0.916
No 9 (81.8) 8 (80.0)
Yes 2 (18.2) 2 (20.0)
*Statistical Test.
Presence or absence of Oct-4 mRNA expression in correlation with the
patients’ baseline characteristics and the outcomes from the assisted
reproduction technologies.perception that this subpopulation has significant char-
acteristics such as pluripotent and self-renewal capabil-
ities. Kossowska et al. (2009) in order to confirm the
multipotency of granulosa cells examined typical mesen-
chymal stem markers and found that CD29, CD44,
CD90, CD105, CD117, and CD166, but not CD73, were
expressed by substantial subpopulations of granulosa
cells. Prolonged culture of luteinizing granulosa cells in
medium supplemented with LIF allowed the selection of
less differentiated granulosa cells, which exhibited a cer-
tain degree of plasticity, as they could be differentiated
in vitro into three distinct lineages: neuronal, chondrocy-
tic, and osteoblastic, all normally not found in healthy
ovarian follicles. Moreover, follicle-derived stem cells
were able to survive when transplanted into the backs of
immunoincompetent mice, in vivo generating tissues of
mesenchymal origin [14].
Recently, the ovarian surface epithelium of adult
human females was reported to be a source of germ
cells. Bukovsky et al. [70] reported the presence of bipo-
tent progenitor cells and Virant-Klun at al [71] reported
stem cells in the adult human ovaries that develop into
oocyte-like and parthenote-like structures [70,71]. Also,
Parte et al. [72] found pluripotent gene transcripts of
Oct-4, Nanog, Sox-2, TERT and STAT-3 in ovarian sur-
face epithelium, while germ cell markers like c-Kit,
DAZL, GDF-9, VASA and ZP4 were localized in oocyte-
like structures. In addition, the bone marrow mesenchy-
mal stem cells were reported to be a source of germ cells
[70,73]. Another important query raised was why the
germline stem cell precursors fail to maintain ovarian
function with advancing age [74]. It is possible that age
associated changes in the immune system could be re-
sponsible for the termination of neo-oogenesis and fol-
licular renewal in vivo [75]. The DAZL gene expression
is a marker for pluripotent stem cells characteristics in
germ cells. However, the expression of DAZL gene in
human granulosa cells remains controversial [68].
Hence, we examined the DAZL gene expression in the
luteinized granulosa cells of women undergoing ovula-
tion stimulation for assisted reproduction, in order to
clarify this controversial field. However, in no case was
the DAZL gene observed to be expressed. This import-
ant result is in concordance with previous findings
reported by Kossowska et al. [14], who did not observe
markers for pluripotent stem cells characteristic of the
germ cells, such as nanog, vasa and stella. Therefore, the
hypothesis that the stem cells found in granulosa cells
cannot be differentiated in germ cells is strongly sup-
ported because of the lack of DAZL, nanog, vasa and
stella gene expression. In addition, Stefanidis et al.
(2009) found that at least in murine induced embryoid
bodies there is simultaneous expression of oxytocin
receptors and germ cell markers (DAZL) in many cells
Table 3 Oct-4 expression – cycle characteristics
Οct-4 expression p-value*
Yes median (IQR) No median (IQR)
Age (ys) 36.00 (35.00, 38.00) 36.00 (30.00, 37.00) 0.520
BMI 23.20 (19.80, 24.60) 22.80 (20.10, 26.30) 0.778
Serum FSH (IU/L) 6.30 (5.80, 7.50) 5.90 (4.30, 8.10) 0.545
SerumLH (IU/L) 4.50 (3.40, 4.60) 5.70 (3.40, 9.70) 0.165
SerumPRL (ng/ml) 11.40 (9.70, 15.30) 10.40 (5.50, 25.10) 0.790
Total gonadotropin dose 2,675.00 (1800.0, 3200.0) 3,112.50 (2325.00, 3675.00) 0.364
Duration of stimulation (ds) 10.00 (9.00, 11.00) 10.00 (9.00, 11.00) 1.000
Serum estradiol on the 5th day of rFSH administration (pg/ml) 500.00 (350.00, 758.00) 455.00 (180.00, 890.00) 0.805
Serum estradiol on the day of hCG administration (pg/ml) 1,800.00 (1,200.00, 2,025.00) 2,283.50 (1,828.00, 2,617.00) 0.149
No of follicles aspirated 8.00 (6.00, 10.00) 8.50 (6.00, 10.00) 0.972
No of oocyte retrieved 8.00 (6.00, 9.00) 8.00 (6.00, 10.00) 0.887
Mature oocytes ratio (%) 75.00 (67.00, 80.0) 68.5 (67.0, 78.0) 0.415
*Statistical Test.
Presence or absence of Oct-4 mRNA expression in correlation with the patients’ cycle characteristics.
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oxytocin might indeed be a molecule playing a leading
role in germ cell determination [36].
A more accurate embryo selection in human assisted
reproduction is needed to optimize and reduce the num-
ber of embryos to be transferred into the uterus in order
to achieve the best balance between reducing the risk of
multiple gestations and maximizing the probability of
pregnancy. Current selection methods are based mainly
on morphological and developmental criteria and in-
clude the speed of cell division (number of blastomeres
at any given stage of development), the regularity of cell
division and the degree of fragmentation [76,77].Figure 3 Levels of Oct-4 expression and FSH levels. There is a trend fo
FSH basal levels, however it did not reach statistical significance (SpearmanMoreover, in some countries, not all retrieved oocytes
can be fertilized due to legal limitations; for example the
Italian legislation allows only three oocytes for each pa-
tient to be fertilized [78]. In such situations, predicting
embryo quality is even more challenging because the
time when the predictive evaluation can be performed is
limited to the interval between oocyte retrieval and
fertilization. This has prompted the search for additional
parameters that can support morphological and meta-
bolic evaluations of the oocyte in order to appropriately
select those that have the greater chance of fertilization
and development. In this respect, the analysis of granu-
losa cells is a good approach for providing suchr negative correlation between Oct-4 mRNA expression levels and the
’s rho=−0.614, p= 0.059).
Figure 4 Levels of Oct-4 expression and peak estradiol levels. There is a statistical non-significant trend for positive correlation between Oct-4
mRNA expression levels and the estradiol peak levels after hCG administration (Spearman’s rho=0.588, p=0.074).
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ment, the granulosa cells differentiate into two distinct
phenotypes, the mural population lining the follicular
antrum and the cumulus population enclosing the
oocyte. The former is essential for oestrogen production
and follicular rupture, while the latter is closely asso-
ciated with oocyte development. Cumulus cell function
is in part regulated by oocyte derived factors and, in
turn, contributes to oocyte maturation and subsequent
developmental potential [9,77]. The cumulus cells, in
fact, are closely connected to the oocyte through a gap
junction network during follicular development and ovu-
lation [79,80]. Following the preovulatory LH surge, the
intercellular connections are broken, but cumulus cells
undergo a process of expansion that continues to bind
these cells to the oocyte throughout the ovulatoryTable 4 Embryo grade – cycle characteristics
Characteristics
Grade 3
Age (years) 36.00 (35.00, 37.00)
FSH (IU/L) 6.00 (4.90, 6.80)
PRL (ng/mL) 11.40 (9.30, 15.90)
Total gonadotropin dosage 2,700.00 (2,275.00, 3,150.00
Serum estradiol, 5th day of rFSH administration
(pg/mL)
546.50 (450.00, 933.00)
Serum estradiol peak (pg/mL) 1,967.50 (1,700.00, 2,467.00
Number of oocytes retrieved 8.00 (6.00, 9.00)
Mature oocyte ratio (%) 71.00 (67.00, 78.00)
Oct-4/G6PD 0.10 (0.10, 98.20)
*Statistical Test.
Embryo grade in correlation with patients’ cycle characteristics and levels of Oct-4/Gprocess and in subsequent fertilization. Characteristics
of the expansion include the secretion of a hyaluronic
acid rich matrix by the granulosa cells and expression of
a number of other proteins required for matrix forma-
tion and retention [76,80-84]. In our study we investi-
gated the expression of Oct-4 in follicular granulosa
cells of women undergoing assisted reproductive tech-
nologies and we think this was a very intriguing ap-
proach. The participating patients in the IVF group gave
written consent for some of the cumulus–mature oocyte
complexes (CMOCs) to be used only for the study.
Therefore the cumulus–mature oocyte complexes
(CMOCs) were randomly selected and manually
denuded separately using a fire-polished tip glass pipette.
These granulosa cells were analyzed for each patient
separately, but the corresponding mature oocytes wereEmbryo grade p
value*Grade 3+2 Grade 2
37.00 (33.00, 39.50) 33.00 (27.00, 37.00) 0.462
7.60 (4.50, 11.40) 6.30 (6.10, 8.10) 0.607
6.00 (3.60, 21.90) 13.80 (4.90, 16.10) 0.581
) 2,387.00 (1,525.00, 3,300.00) 4,000.00 (3,675.00, 4,050.00) 0.029
455.00 (250.50, 633.50) 157.00 (63.00, 309.00) 0.040
) 2,182.50 (1,385.00, 2,800.00) 1,828.00 (1,023.00, 2,022.00) 0.556
8.50 (6.00, 10.50) 8.00 (4.00, 9.00) 0.713
75.00 (63.50, 85.50) 75.00 (50.00, 78.00) 0.887
10.20 (3.10, 628.60) 0.20 (0.00, 0.40) 0.280
6PD genes expression.
Table 5 Clinical pregnancy – cycle characteristics
Characteristics Clinical Pregnancy p
value*No Median [IQR] Yes Median [IQR]
Age (years) 36.00 (33.00, 37.00) 37.50 (35.50, 41.50) 0.238
FSH (IU/L) 6.30 (5.60, 8.00) 4.20 (3.80, 5.50) 0.065
PRL (ng/mL) 10.00 (7.10, 15.30) 16.80 (11.40, 25.10) 0.137
Total gonadotropin dosage 2,987.50 (2,037.50, 3,662.50) 2,512.00 (1,725.00, 3,112.50) 0.345
Serum estradiol, 5th day of rFSH administration (pg/mL) 500.00 (309.00, 758.00) 503.50 (403.50, 729.50) 0.754
Serum estradiol, peak (pg/mL) 1,845.00 (1,570.00, 2,317.00) 2,188.50 (1,466.50, 2,636.00) 0.687
Number of oocytes retrieved 7.00 (6.00, 90.00) 9.00 (7.50, 9.50) 0.468
Mature oocyte ratio (%) 75.00 (67.00, 78.00) 68.50 (67.00, 76.50) 0.719
Oct-4/G6PD 0.30 (0.10, 58.80) 54.20 (10.20, 98.20) 0.296
*Statistical Test.
Clinical pregnancy in correlation with patients’ cycle characteristics and levels of Oct-4/G6PD genes expression.
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of cumulus cells is needed. Only some cumulus – ma-
ture oocytes complexes were donated and the cumulus
cells were taken only from the mature oocytes per pa-
tient. In case of ICSI method, the cumulus-mature
oocytes complexes (CMOCs) were manually denuded
from granulosa cells using a fire-polished tip glass pip-
ette. Granulosa cells from all the mature oocytes per pa-
tient were collected together. ICSI was performed only
in oocytes that were morphologically confirmed to be in
metaphase II with the first polar body extruded (mature
oocytes). In case of the ICSI the cumulus cells were
taken only when they surrounded the mature oocytes
and these were the ones we analyzed. Therefore, the
populations of both groups were homogenous as the cu-
mulus cells in the ICSI group were only from mature
oocytes and not from mature, immature and degener-
ated oocytes. In this way, we examined the expression of
Oct-4 mRNA in granulosa cells from each patient separ-
ately in correlation with duration of ovulation induction,
number of follicles aspirated, number of oocytes
retrieved, number of mature oocytes retrieved, embryo
grade and clinical pregnancy and found a clear clinical
significance only for the number of oocytes retrieved
suggesting that Oct-4 expression positively affects the
oocyte development during ART. The possibility for
stem cell contamination during egg retrieval or granu-
losa cells collection and possible Oct-4 expression
should be excluded because of the absence of DAZL
gene expression, which is typically expressed in gametes.
Our population included only patients with male or
tubal factor infertility. It would be interesting if further
studies investigated expression with any clinical signifi-
cance of Oct-4 gene in granulosa cells of patients with
diminished ovarian reserve (DOR) as such population
was not included in our study. Also, it would be interest-
ing if more studies validated the expression of Oct-4
using Western blot analysis and immune-fluorescenceon granulosa cells in order to overcome possible limita-
tions. Western blot analysis and immune-fluorescence
on granulosa cells are going to reinforce our findings.
Studying any clinical significance in ART of the expres-
sion of stem cell markers in luteinized granulosa cells is
a new field of knowledge and according to our know-
ledge the present study is the first one. Previous studies
on the same field were not done before. More of the
studies were performed to correlate the impact of apop-
tosis or survival factors in granulosa cells with ART
parameters and outcome. Nakahara et al. (1997) sug-
gested that when the quality of eggs is small, measured
by apoptosis in granulosa cells, then the eggs are more
likely to be fertilized by ICSI compared to IVF method
[85]. However, Clavero et al. (2003) found that the rate
of apoptosis in granulosa cells was not associated with
the maturity of the oocyte and the ability for fertilization
in ICSI or the quality of follicles during ovulation induc-
tion [86]. Greenseid et al. (2011) found that IGF1, IGF2
and their receptors are down regulated in ovarian granu-
losa cells of women with diminished ovarian reserve
(DOR) compared to those with normal ovarian reserve
(NOR) undergoing in vitro fertilization (IVF) [87]. Also,
Fujino et al. (2008) studied the expression of survivin
gene in granulosa cells from infertile Japanese patients
and found that the gene expression levels of survivin in
patients with endometriosis were significantly lower than
in patients with male factor infertility. The gene expres-
sion levels of survivin in total pregnant patients were
higher than those in total non pregnant patients [88].
Moreover, Varras et al. (2012) studied only normal
women (male factor infertility) and women with tubal
factor infertility who underwent IVI or ICSI and embryo
transfer [69]. Women with endometriosis or polycystic
ovarian syndrome were not included in their study since
endometriosis and androgens promote apoptosis [85,89].
Varras et al. found a statistically significant increased ex-
pression of survivin in granulosa cells of women who
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http://www.ovarianresearch.com/content/5/1/36had tubal factor infertility compared to normal women
(male factor infertility). Therefore, it seems that survivin
acts a protective role in the ovarian micro-environment.
It is possible that survivin might try to protect ovaries,
with possible influenced perfusion due to ipsilateral sal-
pingectomy. In cases with tubal inflammation or hydro-
salpinges survivin might try to protect the ovaries from
follicular apoptosis in a paracrine environment [69]. The
authors suggested their hypothesis about the levels of
survivin mRNA expression in ovarian granulosa cells in
tubal factor infertility. Some patients in the subpopula-
tion of women with tubal factor undergoing assisted
reproduction and embryo transfer probably could benefit
in assessing oocyte quality by measuring the levels of
survivin expression in their granulosa cells. Therefore, if
the survivin levels in granulosa cells are low, then ICSI
should be concerned, as ICSI is an invasive method and
good oocyte quality is not required. On the other hand,
if survivin levels are highly expressed in granulosa cells
then IVF should be preferred, as IVF is a non-invasive
method and therefore normal sperm-egg interaction and
good oocyte quality is essential [69].
Conclusions
Expression of Oct-4 gene in luteinized granulosa cells
seems to be at a ratio of 48%, and also seems to absent
DAZL gene expression, which possibly suggests the ex-
istence of stem cells not originated from primordial
germ cells. Absence of Oct-4 gene expression means
probably the end of the productive journey of these cells,
towards oocytes. Considering that Oct-4 transcripts
could only be detected in 48%, any clinical significance
seems to be limited. However, we found a clear clinical
significance between the number of oocytes retrieved
and expression levels of Oct-4 mRNA in granulosa cells.
Therefore, when Oct-4 is expressed in granulosa cells
appears to play an important role in the regulation of
follicular growth during ART.
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